These combined effects independently suppress gluconeogenesis and lipogenesis in hepatocytes, offering a promising therapeutic strategy for treating hepatic steatosis via the lncSHGL/hnRNPA1 regulatory axis (Figure 2) [95]. The gene discussed is HNRNPA1; the disease is fatty liver disease.